CU6 - ASX Charts, page-957

I think there is always a reason stocks that enter the 200/300 drop down heavily. In most instances, the MC when it enters has most likely been inflated.

I believe that cu6 may continue to stay strong even until it enters the 200, and this may be held up by the potential buyout potential due to other targets that have occurred with other radiopharma companies in US. But the longer a takeover doesnt occur, the higher the risk this has of going down hard. Revenue won't be realistic until mid to late 2026, and cu67 is technically still P1, with P2 hopefully starting late Q4/Q1.

I strongly believe the science and data is showing great potential, and that eventually clarity will prove that it has the best PSMA assets for diagnostic and therapy by a clear margin, but how long this takes is unknown. Taking profits off the table at this price point is the most logical decision.